AtriCure (ATRC) Reports In-Line Q2 EPS, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $58.97 -0.56%
Revenue Growth %: +12.5%
Financial Fact:
Cost of revenue: 10.87M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +12.5%
Financial Fact:
Cost of revenue: 10.87M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
AtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $116.3 million versus the consensus estimate of $116.18 million.
GUIDANCE:
AtriCure sees FY2024 EPS of ($0.74)-($0.82), versus the consensus of ($0.77). AtriCure sees FY2024 revenue of $456-461 million, versus the consensus of $461.9 million.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
- FDA approves first once-weekly insulin for type 2 diabetes mellitus in pediatric patients
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
